Modality
Cell Therapy
MOA
Cl18.2
Target
VEGF
Pathway
Checkpoint
ALS
Development Pipeline
Preclinical
~May 2016
→ ~Aug 2017
Phase 1
Nov 2017
→ Jul 2028
Phase 1Current
NCT03656170
2,029 pts·ALS
2019-06→2028-07·Active
NCT03263517
1,535 pts·ALS
2017-11→2027-12·Completed
3,564 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-08-245mo awayFast Track· ALS
2027-12-031.7y awayInterim· ALS
2028-07-192.3y awayInterim· ALS
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1
Complet…
P1
Active
Catalysts
Fast Track
2026-08-24 · 5mo away
ALS
Interim
2027-12-03 · 1.7y away
ALS
Interim
2028-07-19 · 2.3y away
ALS
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03656170 | Phase 1 | ALS | Active | 2029 | MRD |
| NCT03263517 | Phase 1 | ALS | Completed | 1535 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| Pemicapivasertib | Legend Biotech | Phase 3 | VEGF | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF | |
| LEG-6533 | Legend Biotech | NDA/BLA | VEGF | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 |